Attovia Therapeutics (ATTO) news
Recent news
Attovia Therapeutics Inc: Leerink Partners initiates coverage with outperform rating; target price $52
Leerink Partners has initiated coverage on Attovia Therapeutics Inc (Nasdaq: ATTO) with an "Outperform" rating and a target price of $52 per share, reinforcing positive sentiment toward the clinical-stage biopharmaceutical company. This follows Attovia’s successful upsized initial public offering…
AInvest Wire · 8h agoAtovia Therapeutics upsized $17M-shr IPO prices at $17/shr
Attovia Therapeutics has priced its upsized initial public offering (IPO) at $17 per share, raising a total of $289 million based on the 17 million shares offered. This represents an increase from the previously targeted $17 million valuation, reflecting strong investor interest in the…
AInvest Wire · Aug 5, 2026Attovia Therapeutics seeks up to $289M in IPO, saw $212.5M
AInvest Wire · Aug 4, 2026Attovia Therapeutics upsizes IPO to 17M shares
AInvest Wire · Aug 4, 2026Attovia Therapeutics - now sees IPO of 17,000,000 common shares - SEC filing
Attovia Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) of 17,000,000 common shares, according to a recent SEC filing. The company submitted a Form S-1 registration statement, which is the standard document required for companies…
AInvest Wire · Aug 4, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.